Qiagen N.V. (QIA.DE) XETRA

40.52

+0.13(+0.32%)

Updated at September 08 05:35PM

Currency In EUR

Qiagen N.V.

Address

Hulsterweg 82

Venlo, 5912 PL

Netherlands

Phone

31 77 355 6600

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

5700

First IPO Date

July 22, 1998

Key Executives

NameTitlePayYear Born
Mr. Thierry BernardChief Executive Officer, MD & Member of Management Board2.09M1964
Dr. Roland SackersChief Financial Officer, MD & Member of Management Board1.08M1968
Mr. Antonio SantosSenior Vice President & Head of Global Operations0N/A
Ms. Stephany FosterSenior Vice President & Head of Human Resources01979
Mr. Jean-Pascal ViolaSenior Vice President & Head of Corporate Strategy and Business Development0N/A
Dr. Thomas TheuringerSenior Director & Head of External Communications0N/A
Dr. Dominic JohnVice President of Marketing & Product Management0N/A
Dr. Jonathan G. Sheldon Ph.D.Senior Vice President & Head of the QIAGEN Digital Insights Business Area01972
Mr. John GilardiVice President of Corporate Communications & Investor Relations0N/A
Dr. Thomas SchweinsSenior Vice President of Life Science Business Area0N/A

Description

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping, and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. It has a strategic alliance agreement with Sysmex Corporation and OncXerna Therapeutics, as well as an agreement with Mirati. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.